Use and continuity of weight-modifying medications among adults with diabetes and overweight/obesity: US population study

Abstract

Objective: Trends in use and continuity of use of diabetes-specific and non-diabetes weight-reducing (WR), weight-inducing (WI), and weight-neutral (WN) medications were examined among US adults with diabetes and overweight/obesity. Methods: Serial cross-sectional data from Medical Expenditure Panel Surveys (2010–2019) for adults (≥18 years) with diabetes and BMI ≥27 kg/m2 (≥25 kg/m2 for Asians) were analyzed. Results: Among 7402 US adults with diabetes and overweight/obesity (mean age 60.0 years [SD 13], 50% female), 64.9% of participants used any WI medications, decreasing from 68.9% (95% CI: 64.3%–73.5%) in 2010 to 58.6% (95% CI: 54.7%–62.5%) in 2019. It was estimated that 13.5% used WR medications, increasing 3.31-fold, from 6.4% (95% CI: 4.1%–8.7%) to 21.2% (95% CI: 18.0%–24.4%) and that 73.1% used WN medications, ranging from 70.5% (95% CI: 66.5–74.6) to 75.0% (95% CI: 71.7%–78.4%). Among adults using diabetes-specific WI (53.7%), WR (7.1%), and WN (62.4%) medications during the first year, 7.3%, 16.4%, and 9.0% discontinued it in the second year, respectively. Conclusions: Over 2010–2019, 64.9% of adults with diabetes and overweight/obesity were treated with WI medications, 13.5% with WR medications, and 73.1% with WN medications. Discontinuation of WR medications was nearly twice that of WI medications.